Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Katy K. Tsai"'
Autor:
Javid Moslehi, Alan H. Baik, Douglas B. Johnson, Olalekan O. Oluwole, Katy K. Tsai, Joe-Elie Salem, Nina Shah
Publikováno v:
Circ Res
Immune-based therapies have revolutionized cancer treatments. Cardiovascular sequelae from these treatments, however, have emerged as critical complications, representing new challenges in cardio-oncology. Immune therapies include a broad range of no
Publikováno v:
Clin Sci (Lond)
Immunotherapies have greatly expanded the armamentarium of cancer-directed therapies in the past decade, allowing the immune system to recognize and fight cancer. Immune checkpoint inhibitors (ICIs), in particular, have revolutionized cancer treatmen
Autor:
Christopher G. Twitty, Lawrence Fong, Mai H. Le, Alan Paciorek, Kathryn Toshimi Takamura, Alain Algazi, Lawrence Chen, Katy K. Tsai, Samantha K. Greaney, Li Zhang, Robert H. Pierce, Adil Daud
Publikováno v:
Cancer immunology research, vol 8, iss 2
Whereas systemic IL12 is associated with potentially life-threatening toxicity, intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites. The mechanism by which th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b224ee83c6bc6097217193ed98064ee8
https://escholarship.org/uc/item/28b0z9wr
https://escholarship.org/uc/item/28b0z9wr
Autor:
Mark B. Faries, Sanjiv S. Agarwala, Bernard A. Fox, Carlo Bifulco, Sharron Gargosky, Donna Bannavong, Christopher G. Twitty, Erica Browning, M. Molina, R. Talia, M.H. Le, Arielle Oglesby, Lawrence Fong, Adil Daud, Katy K. Tsai, Alain Algazi, Carmen Ballesteros-Merino, Shailender Bhatia, M. Franco, Karl D. Lewis, Lauren P. Levine, Robert H. Pierce
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology, vol 31, iss 4
Background Interleukin 12 (IL-12) is a pivotal regulator of innate and adaptive immunity. We conducted a prospective open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT 01502293). Patients and method
Autor:
Jean S. Campbell, Renata Hermiz, Alain Algazi, Donna Bannavong, Michael Rosenblum, Lawrence Fong, Sharron Gargosky, Erica Browning, Christopher Garris, Scot Ebbinhaus, Christopher G. Twitty, Mikael J. Pittet, Adam B. Olshen, Lauren P. Levine, Robert H.I. Andtbacka, Robert H. Pierce, Bernard A. Fox, Ari Oglesby, Shailender Bhatia, Murray Franco, Sean P. Arlaukas, Katy K. Tsai, Mai Le, Dave Canton, Daud Adlil
Publikováno v:
SSRN Electronic Journal.
Non-response to anti-PD-1 antibodies is characterized by a “cold” tumor microenvironment lacking “exhausted” CD8+ T cells. We report on the first prospective Phase 2 trial of intratumoral plasmid IL-12 and pembrolizumab in advanced melanoma w
Autor:
Michael Alvarado, Iryna Lobach, Keyon Taravati, Katy K. Tsai, Mariela L. Pauli, Matthew F. Krummel, Priscila Munoz Sandoval, Miguel Hernandez Pampaloni, Adi Nosrati, Michael Rosenblum, Kimberly Loo, Lorenzo Nardo, Iris K. Gratz, Adil Daud, Robert H. Pierce, Robert Sanchez-Rodriguez, Alain Algazi, Jimmy Hwang
Publikováno v:
The Journal of clinical investigation. 126(9)
BACKGROUND. Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical
Autor:
Katy K. Tsai, Adil Daud
Publikováno v:
Drugs. 75(6)
The discovery of immune inhibitory checkpoints has revolutionized the approach to the systemic treatment of cancer. The programmed death 1 (PD-1) inhibitory checkpoint, in particular, has played a key role in understanding how certain cancers can eva
Autor:
Katy K. Tsai, Christina L Harview, Tristan Grogan, Marko Spasic, Robert Rodriguez, David Elashoff, Niharika Khurana, I. Peter Shintaku, Michael Rosenblum, Phillip J. Sanchez, Paul Camille Tumeh, Jeremy Chang, Adil Daud, Bartosz Chmielowski, Robert H. Pierce, Nathan Handley, Emma Taylor
Publikováno v:
Cancer Research. 75:2857-2857
Therapies that block the PD-1/PD-L1 axis have shown significant clinical activity in melanoma and other cancers. Recent evidence has shown that pre-existing CD8 T cells infiltrates at the invasive tumor margin of metastatic melanoma are associated wi
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Autor:
Mai Le, Shailender Bhatia, Carmen Ballesteros-Merino, Adil Daud, Murray Francisco, Christopher G. Twitty, Erica Browning, Reneta Hermiz, Mikael J. Pittet, Arielle Oglesby, Sharron Gargosky, Katy K. Tsai, Christopher Garris, Lawrence Fong, Michael Rosenblum, Bernard A. Fox, Robert H.I. Andtbacka, David A. Canton, Alain Algazi, Carlos Bifulco, Lauren P. Levine, Donna Bannavong, Sean P. Arlauckas, Robert H. Pierce
Publikováno v:
BASE-Bielefeld Academic Search Engine
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 12
Clin Cancer Res
Clinical Cancer Research, Vol. 26, No 12 (2020) pp. 2827-2837
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 12
Clin Cancer Res
Clinical Cancer Research, Vol. 26, No 12 (2020) pp. 2827-2837
Purpose: Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade. We conducted a prospective multicenter phase II trial of intratumoral plasmid IL-12 (tavokinogene t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d86693cc71daf5a3684a1122cd1bce
https://escholarship.org/uc/item/59t2b8v3
https://escholarship.org/uc/item/59t2b8v3